Digest Network Come funziona
Network
/
Società
Bo
Non verificato

Boehringer Ingelheim

Di cosa scriviamo

FarmaceuticaImpreseIndustriaMedicina Salute BenesserePubblicità/Marketing/Media/Comunicazione

12 comunicati stampa

Guarda tutti i comunicati
Press Release cover image
22/11/2024
Farmaceutica
Sanità
Economia
Start-up
Boehringer Ingelheim launches VETMEDIN® Solution (pimobendan oral solution), first oral solution approved by the FDA for congestive heart failure in dogs
Fonte
Boehringer Ingelheim
Emittente
PR News Wire
1,00
0
07/10/2024
Farmaceutica
Medicina Salute Benessere
Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two phase III trials in MASH for survodutide
Fonte
Boehringer Ingelheim
Emittente
GLOBENEWSWIRE
1,00
0
27/09/2024
Farmaceutica
Medicina Salute Benessere
Boehringer Ingelheim partners with NCD Alliance to target Non-Communicable Diseases in underserved communities
Fonte
Boehringer Ingelheim
Emittente
GLOBENEWSWIRE
1,00
0
25/09/2024
Farmaceutica
Medicina Salute Benessere
Boehringer Ingelheim expands cancer research at its Vienna site
Fonte
Boehringer Ingelheim
Emittente
GLOBENEWSWIRE
1,00
0
16/09/2024
Farmaceutica
Medicina Salute Benessere
Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study
Fonte
Boehringer Ingelheim
Emittente
GLOBENEWSWIRE
1,00
0
09/09/2024
Farmaceutica
Medicina Salute Benessere
Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients
Fonte
Boehringer Ingelheim
Emittente
GLOBENEWSWIRE
1,00
0
05/09/2024
Farmaceutica
Medicina Salute Benessere
Boehringer Ingelheim announces plans to advance potential new treatment for Geographic Atrophy, following positive Phase I results
Fonte
Boehringer Ingelheim
Emittente
GLOBENEWSWIRE
1,00
0
03/09/2024
Farmaceutica
Pubblicità/Marketing/Media/Comunicazione
Boehringer Ingelheim acquires Saiba Animal Health, adding innovative technology platform to its pet therapeutics R&D portfolio
Fonte
Boehringer Ingelheim
Emittente
GLOBENEWSWIRE
1,00
0
28/07/2024
Farmaceutica
Medicina Salute Benessere
CHMP adopts positive opinion recommending approval of new and expanded indications for SPEVIGO®
Fonte
Boehringer Ingelheim
Emittente
GLOBENEWSWIRE
1,00
0
18/07/2024
Farmaceutica
Medicina Salute Benessere
First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones
Fonte
Boehringer Ingelheim
Emittente
GLOBENEWSWIRE
1,00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0